| Miss Sarah Nicole Barbuto, MS | |
|
435 E Alder St, Alsea, OR 97324-9634 | |
| (541) 487-7116 | |
| (541) 487-4076 |
| Full Name | Miss Sarah Nicole Barbuto |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 435 E Alder St, Alsea, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750757944 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Miss Sarah Nicole Barbuto, MS 530 Nw 27th St, Corvallis, OR 97330-5223 Ph: (541) 766-6835 | Miss Sarah Nicole Barbuto, MS 435 E Alder St, Alsea, OR 97324-9634 Ph: (541) 487-7116 |
News Archive
OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.
The body's endocannabinoid system, due to the critical role it plays in regulating neurotransmitter signaling, is an enticing target for drug development against disorders associated with anxiety, stress, and repetitive behaviors, such as obsessive-compulsive disorder.
In this interview, News-Medical speaks to Dr. Tillmann Ziegert, Managing Director at Biorbyt Ltd, about the balance between enhancing ethical research opportunities and keeping customers at center stage.
A new type of immunotherapy shows promise against cases of acute myeloid leukemia (AML) that recur after treatment or that never respond to therapy in the first place.
› Verified 5 days ago